These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

479 related articles for article (PubMed ID: 26657830)

  • 1. CSAHi study: Evaluation of multi-electrode array in combination with human iPS cell-derived cardiomyocytes to predict drug-induced QT prolongation and arrhythmia--effects of 7 reference compounds at 10 facilities.
    Kitaguchi T; Moriyama Y; Taniguchi T; Ojima A; Ando H; Uda T; Otabe K; Oguchi M; Shimizu S; Saito H; Morita M; Toratani A; Asayama M; Yamamoto W; Matsumoto E; Saji D; Ohnaka H; Tanaka K; Washio I; Miyamoto N
    J Pharmacol Toxicol Methods; 2016; 78():93-102. PubMed ID: 26657830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CSAHi study: Validation of multi-electrode array systems (MEA60/2100) for prediction of drug-induced proarrhythmia using human iPS cell-derived cardiomyocytes -assessment of inter-facility and cells lot-to-lot-variability.
    Nozaki Y; Honda Y; Watanabe H; Saiki S; Koyabu K; Itoh T; Nagasawa C; Nakamori C; Nakayama C; Iwasaki H; Suzuki S; Washio I; Takahashi E; Miyamoto K; Yamanishi A; Endo H; Shinozaki J; Nogawa H; Kunimatsu T
    Regul Toxicol Pharmacol; 2016 Jun; 77():75-86. PubMed ID: 26884090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CSAHi study: Detection of drug-induced ion channel/receptor responses, QT prolongation, and arrhythmia using multi-electrode arrays in combination with human induced pluripotent stem cell-derived cardiomyocytes.
    Kitaguchi T; Moriyama Y; Taniguchi T; Maeda S; Ando H; Uda T; Otabe K; Oguchi M; Shimizu S; Saito H; Toratani A; Asayama M; Yamamoto W; Matsumoto E; Saji D; Ohnaka H; Miyamoto N
    J Pharmacol Toxicol Methods; 2017; 85():73-81. PubMed ID: 28163191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Availability of human induced pluripotent stem cell-derived cardiomyocytes in assessment of drug potential for QT prolongation.
    Nozaki Y; Honda Y; Tsujimoto S; Watanabe H; Kunimatsu T; Funabashi H
    Toxicol Appl Pharmacol; 2014 Jul; 278(1):72-7. PubMed ID: 24742750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement of acquisition and analysis methods in multi-electrode array experiments with iPS cell-derived cardiomyocytes.
    Asakura K; Hayashi S; Ojima A; Taniguchi T; Miyamoto N; Nakamori C; Nagasawa C; Kitamura T; Osada T; Honda Y; Kasai C; Ando H; Kanda Y; Sekino Y; Sawada K
    J Pharmacol Toxicol Methods; 2015; 75():17-26. PubMed ID: 25910965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CSAHi study-2: Validation of multi-electrode array systems (MEA60/2100) for prediction of drug-induced proarrhythmia using human iPS cell-derived cardiomyocytes: Assessment of reference compounds and comparison with non-clinical studies and clinical information.
    Nozaki Y; Honda Y; Watanabe H; Saiki S; Koyabu K; Itoh T; Nagasawa C; Nakamori C; Nakayama C; Iwasaki H; Suzuki S; Tanaka K; Takahashi E; Miyamoto K; Morimura K; Yamanishi A; Endo H; Shinozaki J; Nogawa H; Shinozawa T; Saito F; Kunimatsu T
    Regul Toxicol Pharmacol; 2017 Aug; 88():238-251. PubMed ID: 28634147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive in vitro cardiac safety assessment using human stem cell technology: Overview of CSAHi HEART initiative.
    Takasuna K; Asakura K; Araki S; Ando H; Kazusa K; Kitaguchi T; Kunimatsu T; Suzuki S; Miyamoto N
    J Pharmacol Toxicol Methods; 2017; 83():42-54. PubMed ID: 27646297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of high glucose and insulin on the electrophysiological properties of cardiomyocytes derived from human-induced pluripotent stem cells.
    Wei F; Zhang Y; Wang X; Huo J
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2022 May; 47(5):610-618. PubMed ID: 35753731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-throughput cardiac safety evaluation and multi-parameter arrhythmia profiling of cardiomyocytes using microelectrode arrays.
    Gilchrist KH; Lewis GF; Gay EA; Sellgren KL; Grego S
    Toxicol Appl Pharmacol; 2015 Oct; 288(2):249-57. PubMed ID: 26232523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative analysis of media effects on human induced pluripotent stem cell-derived cardiomyocytes in proarrhythmia risk assessment.
    Schocken D; Stohlman J; Vicente J; Chan D; Patel D; Matta MK; Patel V; Brock M; Millard D; Ross J; Strauss DG; Blinova K
    J Pharmacol Toxicol Methods; 2018; 90():39-47. PubMed ID: 29155283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of extracellular field potential and Ca
    Abi-Gerges N; Pointon A; Oldman KL; Brown MR; Pilling MA; Sefton CE; Garside H; Pollard CE
    J Pharmacol Toxicol Methods; 2017; 83():1-15. PubMed ID: 27622857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of optical action potentials in human induced pluripotent stem cells-derived cardiomyocytes to predict drug-induced cardiac arrhythmias.
    Lu HR; Hortigon-Vinagre MP; Zamora V; Kopljar I; De Bondt A; Gallacher DJ; Smith G
    J Pharmacol Toxicol Methods; 2017 Sep; 87():53-67. PubMed ID: 28501647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive Cardiac Safety Assessment using hiPS-cardiomyocytes (Consortium for Safety Assessment using Human iPS Cells: CSAHi).
    Takasuna K; Kazusa K; Hayakawa T
    Curr Pharm Biotechnol; 2020; 21(9):829-841. PubMed ID: 31749424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proarrhythmia Risk Assessment in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes Using the Maestro MEA Platform.
    Qu Y; Vargas HM
    Toxicol Sci; 2015 Sep; 147(1):286-95. PubMed ID: 26117837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Electrophysiological characteristics and pharmacological sensitivity of two lines of human induced pluripotent stem cell derived cardiomyocytes coming from two different suppliers.
    Goineau S; Castagné V
    J Pharmacol Toxicol Methods; 2018; 90():58-66. PubMed ID: 29274391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of Proarrhythmic Potential of Drugs in Optogenetically Paced Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
    Patel D; Stohlman J; Dang Q; Strauss DG; Blinova K
    Toxicol Sci; 2019 Jul; 170(1):167-179. PubMed ID: 30912807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proarrhythmia risk prediction using human induced pluripotent stem cell-derived cardiomyocytes.
    Yamazaki D; Kitaguchi T; Ishimura M; Taniguchi T; Yamanishi A; Saji D; Takahashi E; Oguchi M; Moriyama Y; Maeda S; Miyamoto K; Morimura K; Ohnaka H; Tashibu H; Sekino Y; Miyamoto N; Kanda Y
    J Pharmacol Sci; 2018 Apr; 136(4):249-256. PubMed ID: 29555184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multi-parametric assessment of cardiomyocyte excitation-contraction coupling using impedance and field potential recording: A tool for cardiac safety assessment.
    Zhang X; Guo L; Zeng H; White SL; Furniss M; Balasubramanian B; Lis E; Lagrutta A; Sannajust F; Zhao LL; Xi B; Wang X; Davis M; Abassi YA
    J Pharmacol Toxicol Methods; 2016; 81():201-16. PubMed ID: 27282640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive Translational Assessment of Human-Induced Pluripotent Stem Cell Derived Cardiomyocytes for Evaluating Drug-Induced Arrhythmias.
    Blinova K; Stohlman J; Vicente J; Chan D; Johannesen L; Hortigon-Vinagre MP; Zamora V; Smith G; Crumb WJ; Pang L; Lyn-Cook B; Ross J; Brock M; Chvatal S; Millard D; Galeotti L; Stockbridge N; Strauss DG
    Toxicol Sci; 2017 Jan; 155(1):234-247. PubMed ID: 27701120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Points to consider for a validation study of iPS cell-derived cardiomyocytes using a multi-electrode array system.
    Kanda Y; Yamazaki D; Kurokawa J; Inutsuka T; Sekino Y
    J Pharmacol Toxicol Methods; 2016; 81():196-200. PubMed ID: 27369811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.